EU-AVP-D Study

• Research type

  Research Study

• Full title

  European Arginine Vasopressin Deficiency [central diabetes insipidus] Study – the EU-AVP-D Study

• IRAS ID

  343866

• Contact name

  Miles Levy

• Contact email

  miles.j.levy@uhl-tr.nhs.uk

• Sponsor organisation

  University of Basel

• Duration of Study in the UK

  4 years, 9 months, 0 days

• Research summary

  AVP deficiency is a rare condition, and data on clinical characteristics, desmopressin-related side effects, and treatment errors or complications during hospitalisations are generally limited to small studies and case reports. We decided, together with other experts in the field, to collect data on this condition in leading European pituitary centres.
  This multicentre observational cohort study aims to assess clinical characteristics and disease-related complications (e.g., the prevalence of desmopressin-induced side-effects, episodes of hypernatraemic dehydration due to inappropriate fluid management, treatment errors due to confusion with ‘diabetes mellitus’ etc.), and psychological co-morbidities. Furthermore, this study aims to prospectively evaluate over a 5-year observation period for each patient whether recent changes, such as attention to the ‘desmopressin escape’ method or renaming of the disease, might have an impact on hyponatraemia rates and in-hospital adverse events.
  

• REC name

  London - City & East Research Ethics Committee

• REC reference

  25/PR/0097

• Date of REC Opinion

  5 Feb 2025

• REC opinion

  Favourable Opinion